Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Cao, Jing Yan ^a,b   Liu, Li ^a   Chen, Shu Peng ^a   Zhang, Xing ^a   Mi, Yan Jun ^a   Liu, Zhi Gang ^a   Li, Man Zhi ^a   Zhang, Hua ^a   Qian, Chao Nan ^a   Shao, Jian Yong ^a   Fu, Li Wu ^a   Xia, Yun Fei ^a   Zeng, Mu Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CENTROMERE PROTEIN F; CHROMOSOME PROTEIN; CISPLATIN; COMPLEMENTARY DNA; MESSENGER RNA; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PARAFFIN; TUMOR MARKER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; METHIONINE; NONHISTONE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL ASSAY; CELL IMMORTALIZATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DISTANT METASTASIS; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; FROZEN SECTION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKULL BASE TUMOR; SURVIVAL TIME; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CHROMOSOMAL PROTEINS, NON-HISTONE; CISPLATIN; DIPHOSPHONATES; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; METHIONINE; MICROFILAMENT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 77956479428     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-237     Document Type: Article

References (43)

1. Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 2006, 6:178. 10.1186/1471-2407-6-178, 1557527, 16822324.
2. Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ. A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer 2000, 89:242-247. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z, 10918151.
3. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462. 10.1016/S1044579X02000883, 12450731.
4. Yamashita S, Kondo M, Hashimoto S. Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy. Acta Radiol Oncol 1985, 24:315-320. 10.3109/02841868509136058, 2994387.
5. Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH. Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope 1992, 102:965-972.
6. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994, 21:382-397.
7. Bomont P, Maddox P, Shah JV, Desai AB, Cleveland DW. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. Embo J 2005, 24:3927-3939. 10.1038/sj.emboj.7600848, 1283947, 16252009.
8. Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci 2005, 118:4889-4900. 10.1242/jcs.02614, 16219694.
9. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol 1995, 130:507-518. 10.1083/jcb.130.3.507, 2120529, 7542657.
10. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 2002, 115:3403-3414.
11. Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma 2006, 115:288-295. 10.1007/s00412-005-0046-0, 16565862.
12. Ma L, Zhao X, Zhu X. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci 2006, 13:205-213. 10.1007/s11373-005-9057-3, 16456711.
13. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007, 6:1317-1328. 10.1158/1535-7163.MCT-06-0703, 17431110.
14. Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med 2009,
15. Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler MJ. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997, 20:308-319.
16. Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G. Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod Pathol 1999, 12:69-74.
17. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N. Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol 2005, 41:716-722. 10.1016/j.oraloncology.2005.03.008, 15927522.
18. Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol 2005, 18:1223-1231. 10.1038/modpathol.3800409, 15933757.
19. Konstantinidou AE, Korkolopoulou P, Kavantzas N, Mahera H, Thymara I, Kotsiakis X, Perdiki M, Patsouris E, Davaris P. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol Histopathol 2003, 18:67-74.
20. O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007, 120:1434-1443. 10.1002/ijc.22413, 17205517.
21. Shao JY, Zeng WF, Zeng YX. [Molecular genetic progression on nasopharyngeal carcinoma]. Ai Zheng 2002, 21:1-10.
22. Li RP, Shao JY, Deng L, Zeng MS, Song LB, Li MZ, Wu QL. [Identification of differentially expressed genes in primary cultured nasopharyngeal carcinoma cells by cDNA microarray]. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:1156-1160.
23. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008, 20:264-269. 10.1097/CCO.0b013e3282fad846, 18391624.
24. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236. 10.1177/009127002762491316, 12412821.
25. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004, 53:235-240. 10.1136/gut.2003.021238, 1774925, 14724156.
26. de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A. CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck 2001, 23:104-112. 10.1002/1097-0347(200102)23:2<104::AID-HED1005>3.0.CO;2-0, 11303627.
27. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043-1048. 10.1038/ng1861, 16921376.
28. Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick UJ, Pawitan Y, Alaiya A, Sennerstam R, Zetterberg A, Auer G. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res 2004, 64:904-909. 10.1158/0008-5472.CAN-03-2451, 14871819.
29. Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 2010, 10:102-115. 10.1038/nrc2781, 20094045.
30. Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y, Tsao SW. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000, 21:2293-2297. 10.1093/carcin/21.12.2293, 11133821.
31. Mao Y, Desai A, Cleveland DW. Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol 2005, 170:873-880. 10.1083/jcb.200505040, 2171436, 16144904.
32. Schaar BT, Chan GK, Maddox P, Salmon ED, Yen TJ. CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol 1997, 139:1373-1382. 10.1083/jcb.139.6.1373, 2132614, 9396744.
33. Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 2002, 3:351-365. 10.1016/S1534-5807(02)00255-1, 12361599.
34. Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T, Yoda K, Nomura F. Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res 2005, 65:4683-4689. 10.1158/0008-5472.CAN-04-3613, 15930286.
35. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res 2007, 13:508-514. 10.1158/1078-0432.CCR-06-1512, 17255272.
36. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974. 10.1158/0008-5472.CAN-05-0264, 15958534.
37. Green JR. Bisphosphonates: preclinical review. Oncologist 2004, 9(Suppl 4):3-13. 10.1634/theoncologist.9-90004-3, 15459425.
38. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 107:5839-5844. 10.1073/pnas.0915068107, 20167803.
39. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232. 10.1158/0008-5472.CAN-06-0094, 16778197.
40. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004, 10:8465-8471. 10.1158/1078-0432.CCR-04-0653, 15623626.
41. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6:4064-4068.
42. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006, 5:39-47.
43. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004, 25:146-147.